ArticleMissouri medicine
What the Non-Psychiatrist Should Know About Transcranial Magnetic Stimulation for Major Depression.
Article in Missouri medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation treatment for major depressive disorder. Randomized controlled trials show response rates twice times higher for TMS (23.9%) than placebo (12.3%) in adults with depression. Real world studies showed increased response rates up to 58% in clinically heterogenous adult patient populations. TMS is safe and well tolerated with a benign side effect profile and high adherence. Standard TMS protocols include left dorso-lateral prefrontal cortex stimulation using a fixed stimulation protocol or burst-patterned protocols such as intermittent theta burst delivered over six weeks. Novel accelerated protocols using high daily dosing and functional MRI targeting provide increased precision and improved treatment outcomes. TMS shows effectiveness in patients with comorbid anxiety, older adults and adolescents for which received FDA approval in 2024. Future studies incorporating neuroimaging techniques may help to refine protocols leading to improved outcomes across different patient populations.
Indexed as
Identifiers
41438926PMC12721854What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.